Home > Drugs A – Z > Amlodipine (By mouth)

Amlodipine (By mouth)

Treats high blood pressure and angina (chest pain). This medicine is a calcium channel blocker.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Amlodipine is used alone or together with other medicines to treat angina (chest pain) and high blood pressure (hypertension). High blood pressure adds to the workload of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney Read more
Brand names include
Norvasc
Drug classes About this
Antianginal, Antihypertensive, Cardiovascular Agent
Combinations including this drug

What works? Research summarized

Evidence reviews

Aliskiren / Amlodipine -- Benefit Assessment According to §35a Social Code Book V [Internet]

The benefit assessment of the fixed combination aliskiren / amlodipine was carried out for the therapeutic indication “treatment of essential hypertension in adults whose blood pressure is not adequately controlled with aliskiren or amlodipine used alone”.

Efficacy of amlodipine for diabetes mellitus combined with hypertension and renal impairment: a systematic review

Bibliographic details: Hu QP, Li YM, Jiang L, Luo TY, Han LN, Li Q, Xie B.  Efficacy of amlodipine for diabetes mellitus combined with hypertension and renal impairment: a systematic review. Chinese Journal of Evidence-Based Medicine 2014; 14(10): 1234-1240 Available from: http://www.cjebm.org.cn/en/oa/darticle.aspx?type=view&id=20141009

Aliskiren and amlodipine in the management of essential hypertension: meta-analysis of randomized controlled trials

BACKGROUND: Aliskiren is a novel renin-angiotensin aldosterone system (RAAS) inhibitor, the combination therapy of aliskiren and amlodipine for blood pressure control have been reported recently. The primary objective of this analysis is to review recently reported randomized controlled trials (RCTs) to compare antihypertensive effects and adverse events between mono (amlodipine or aliskiren alone) and combination therapy of both medicines.

See all (90)

Summaries for consumers

Is the blood pressure lowering effect of dihydropyridine calcium channel blockers consistent or variable throughout 24 hours?

High blood pressure, also known as hypertension, is a risk factor for adverse cardiovascular events such as stroke and heart attack. Blood pressure varies widely in an individual but certain patterns in its rise and fall have been identified in the general population; blood pressure increases in the early morning hours and decreases during the night. There is a variety of treatment options available for treating high blood pressure. Dihydropyridine calcium channel blockers are a group of drugs used to lower blood pressure.

Calcium channel blocking drugs for Duchenne muscular dystrophy

Duchenne muscular dystrophy is a progressive wasting condition of muscles which starts in early childhood, leads to dependence on a wheelchair by the age of thirteen and respiratory failure by late teens. The condition is due to absence of dystrophin, a large muscle protein that has several functions within muscle cells. We know that calcium molecules build up in the muscle cells of people with Duchenne muscular dystrophy and this is associated with cell death. The rationale behind this review was to ascertain whether randomised controlled trials using drugs that block calcium entry into muscle would result in a reduction in progression of the condition. Although these trials were conducted over ten years ago a systematic review was not done at that time, and so a potential effect of calcium blocking drugs (antagonists) on the course of DMD may have been missed. If it were to exist, calcium antagonists might be an effective treatment in their own right or, more likely, could be used in combination with newer treatments such as corticosteroids or potential treatments such as gene related therapies.

PubMed Health Blog...

read all...